Novel treatment strategies utilizing immune reactions against chronic myelogenous leukemia stem cells

研究成果: Review article査読

抄録

Introduction of tyrosine kinase inhibitors (TKIs) has improved the prognosis of patients with chronic myelogenous leukemia (CML), and treatment-free remission (TFR) is now a treatment goal. However, about half of the patients experience molecular relapse after cessation of TKIs, suggesting that leukemic stem cells (LSCs) are resistant to TKIs. Eradication of the remaining LSCs using immunotherapies including interferon-alpha, vaccinations, CAR-T cells, and other drugs would be a key strategy to achieve TFR.

本文言語English
論文番号5435
ジャーナルCancers
13
21
DOI
出版ステータスPublished - 2021 11月 1

ASJC Scopus subject areas

  • 腫瘍学
  • 癌研究

フィンガープリント

「Novel treatment strategies utilizing immune reactions against chronic myelogenous leukemia stem cells」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル